Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epirubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL12349863 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL1501770 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21184881 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14227487 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL24421866 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL14562311 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL23365786 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22403027 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21914951 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL22291815 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279918-A1 | Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-04 | — | — | US | claimed |
| US-4853221-A | Method for treating non-small cell lung cancer, head and neck cancers and breast cancer | WARNER-LAMBERT COMPANY (US) | 1989-08-01 | — | — | US | claimed |
| EP-2671581-B1 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20140140929-A1 | CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS | TEDEBARK, ULF (SE) | 2014-05-22 | — | — | US | disclosed |
| EP-2671581-A2 | Compositions and methods for treating cancer | Threshold Pharmaceuticals, Inc. (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130011448-A1 | SYSTEM FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2013-01-10 | — | — | US | disclosed |
| US-20110212028-A1 | CHEMICALLY MODIFIED CELL-PENETRATING PEPTIDES FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2011-09-01 | — | — | US | disclosed |
| EP-1991586-B1 | CHIMERIC CONSTRUCTS BETWEEN CANCER-HOMING PEPTIDES AND CELL-PENETRATING PEPTIDES COUPLED TO ANTICANCER DRUGS AND/OR DIAGNOSTIC AGENT/AGENTS | CEPEP III AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100279918-A1 | Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-11-04 | — | — | US | disclosed |
| US-7550496-B2 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080132458-A1 | Hypoxia-Activated Anti-Cancer Agents | THRESHOLD PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1599196-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Threshold Pharmaceuticals, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050245462-A1 | Treatment of cancer with 2-deoxyglucose | THRESHOLD PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| EP-1587519-A2 | TREATMENT OF CANCER WITH 2-DEOXYGLUCOSE | Threshold Pharmaceuticals, Inc. (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004087075-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040167079-A1 | Treatment of cancer with 2-deoxyglucose | THRESHOLD PHARMACEUTICALS, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004064734-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004062604-A2 | TREATMENT OF CANCER WITH 2-DEOXYGLUCOSE | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040029815-A1 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-4853221-A | Method for treating non-small cell lung cancer, head and neck cancers and breast cancer | WARNER-LAMBERT COMPANY (US) | 1989-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130011448-A1 | SYSTEM FOR IMPROVED DELIVERY OF GENE MODULATING COMPOUNDS | PHAX, ABCB1, BCR | TOP2A 1574/4885MEN1 3876/4885KMT2A 4122/4885 |
| US-20050245462-A1 | Treatment of cancer with 2-deoxyglucose | UGGT1, G6PD, SLC5A2 | TOP2A 80/4885MEN1 1019/4885KMT2A 974/4885 |
| US-20040029815-A1 | Compositions and methods for treating cancer | SLC2A2, SLC2A1, SLC2A3 | TOP2A 228/4885MEN1 904/4885KMT2A 3182/4885 |
| US-20080132458-A1 | Hypoxia-Activated Anti-Cancer Agents | HIF1AN, HIF1A, HYOU1 | TOP2A 119/4885MEN1 4172/4885KMT2A 1503/4885 |
| US-20040167079-A1 | Treatment of cancer with 2-deoxyglucose | UGGT1, G6PD, SLC5A2 | TOP2A 80/4885MEN1 1019/4885KMT2A 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.